- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- trastuzumab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 961–984
of 3,622
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Non-Small Cell Lung Carcinoma, Solid Tumor, Adult
- Interventions
- Exatherm-TBH system
- Device
- Lead sponsor
- Jonathan Kiev
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Lung Cancer
- Interventions
- Questionnaires, Meditation and Discussion Sessions, Cancer-Related Discussion Program
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer, Prostate Cancer, Urothelial Carcinoma, Colorectal Cancer, Triple Negative Breast Cancer, High Grade Ovarian Serous Adenocarcinoma, Diffuse Large B Cell Lymphoma, Renal Cell Cancer Metastatic
- Interventions
- ZM008
- Biological
- Lead sponsor
- Zumutor Biologics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Austin, TX 78758, Texas • San Antonio, Texas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Decision support tool
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2
- Interventions
- CGT4255
- Drug
- Lead sponsor
- Cogent Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more
- Conditions
- Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Bladder Cancer
- Interventions
- MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
- Drug
- Lead sponsor
- 4D pharma plc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Kansas City, Kansas • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Clinical Observation, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1403
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 888 more
- Conditions
- Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab
- Other · Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Interventions
- brentuximab vedotin, pembrolizumab
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 90
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 57 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- AMG 510, MVASI
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer
- Interventions
- apricoxib, Placebo, Docetaxel or Pemetrexed
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Miami, Florida • Chicago, Illinois + 8 more
- Conditions
- Non-Small-Cell-Lung Cancer (NSCLC)
- Interventions
- 18F-FMISO, PET/CT
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Docetaxel, Gemcitabine, Lurbinectedin (PM01183)
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lung Cancer
- Interventions
- cisplatin, pemetrexed disodium, adjuvant therapy, therapeutic conventional surgery, fludeoxyglucose F 18
- Drug · Procedure · Radiation
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Non-squamous Lung Cancer, Metastatic Lung Cancer
- Interventions
- Blood, sputum, saliva, stool
- Other
- Lead sponsor
- University Hospital, Tours
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Lorlatinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma, Advanced Malignancies Except Leukemia
- Interventions
- PF-02341066, Rifampin, Itraconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 596 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2022
- U.S. locations
- 24
- States / cities
- Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer
- Interventions
- Nivolumab, oral decitabine, Tetrahydrouridine
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Cleveland, Ohio
- Conditions
- NSCLC
- Interventions
- Doxorubicin HCl Inhalation Solution, Docetaxel, Cisplatin
- Drug
- Lead sponsor
- Zivena
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Las Vegas, Nevada • The Bronx, New York + 2 more
- Conditions
- Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Lymph Node Biopsy, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration
- Procedure · Radiation · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
- Interventions
- EIK1001, Pembrolizumab (KEYTRUDA®), Placebo, Paclitaxel + Carboplatin, Nab-paclitaxel + Carboplatin, Pemetrexed + Cisplatin /Carboplatin
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2040
- U.S. locations
- 18
- States / cities
- Daphne, Alabama • Glendale, California • Orange, California + 15 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- XL647
- Drug
- Lead sponsor
- Kadmon Corporation, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 10
- States / cities
- Gilroy, California • Sacramento, California • Stanford, California + 7 more
- Conditions
- Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
- Interventions
- Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Fort Wayne, Indiana • Lexington, Kentucky + 3 more